Landos Biopharma Inc

-0.19 (-1.56%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)477.46M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$9 Million
Adjusted EPS-$0.14
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Landos Biopharma Inc Stock, NASDAQ:LABP

1800 Kraft Drive, Suite 216, Blacksburg, Virginia 24060
United States of America
Phone: +1.540.218.2232
Number of Employees: 33


Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohnâ??s disease that targets the LANCL2 pathway. It also offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.